<p>OmniAb, Inc.（納斯達克代碼：OABI - 獲取免費報告）內部人士 Charles Berkman 於 12 月 8 日星期一出售了 8,044 股 OmniAb 股票。該股票的平均售價為 1.96 美元，總價值為 15,766.24 美元。出售後，該內部人士直接持有公司 377,071 股股票，估值約為 739,059.16 美元。此次交易使其持股比例減少了 2.09%。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，相關信息可通過 SEC 網站訪問。</p>
<h2>OmniAb 價格表現</h2>
<p>納斯達克 OABI 的股票在星期二開盤價為 1.99 美元。該公司的市值為 2.8648 億美元，市盈率為-3.43，貝塔值為 0.13。該股票的 50 日移動平均價格為 1.65 美元，200 日移動平均價格為 1.71 美元。OmniAb, Inc.的年內最低價為 1.22 美元，最高價為 4.17 美元。</p>
<p>OmniAb（納斯達克：OABI - 獲取免費報告）最近一次發佈財報是在 11 月 4 日星期二。公司報告本季度每股收益為（0.14）美元，超出分析師一致預期的（0.15）美元，超出幅度為 0.01 美元。OmniAb 的股本回報率為負的 23.14%，淨利潤率為負的 301.83%。該公司本季度的收入為 224 萬美元，而一致預期為 564 萬美元。平均而言，股票分析師預計 OmniAb, Inc.在當前財政年度的每股收益為-0.61 美元。</p>
<h2>對 OmniAb 的對沖基金看法</h2>
<p>對沖基金最近買入和賣出了該公司的股票。製造商人壽保險公司在第二季度將其在 OmniAb 的持股比例提高了 20.5%。製造商人壽保險公司現在持有 44,809 股公司股票，價值 78,000 美元，此前在上個季度又購買了 7,624 股。Murchinson Ltd.在第一季度將其在 OmniAb 的持股比例提高了 0.8%。Murchinson Ltd.現在持有 1,007,810 股公司股票，價值 2,419,000 美元，此前在上個季度又收購了 7,810 股。Rhumbline Advisers 在第二季度將其在 OmniAb 的持股比例提高了 6.0%。Rhumbline Advisers 現在持有 160,728 股公司股票，價值 280,000 美元，此前在上個季度又收購了 9,163 股。Osaic Holdings Inc.在第二季度將其在 OmniAb 的持股比例提高了 214.4%。Osaic Holdings Inc.現在持有 14,247 股公司股票，價值 25,000 美元，此前在上個季度又購買了 9,716 股。最後，AQR Capital Management LLC 在第一季度收購了 OmniAb 的新頭寸，價值約為 25,000 美元。72.08% 的股票由機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 12 月 1 日星期一的報告中重新發布了對 OmniAb 股票的 “賣出（d-）” 評級。三位投資分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 6.67 美元。</p>
<p><strong>查看我們對 OmniAb 的最新分析</strong></p>
<h2>關於 OmniAb</h2>
<p>（獲取免費報告）</p>
<p>OmniAb, Inc.是一家生物技術公司，專注於在美國發現和提供治療性抗體發現技術。該公司的技術平台創建並篩選多樣化的抗體庫，併為合作伙伴的藥物開發工作識別最佳抗體。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 OmniAb 更好</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>為什麼這三隻汽車和工業芯片股票剛剛飆升</li>
<li>什麼是分紅成就者？簡介</li>
<li>根據 MarketBeat，評級最高的五隻分紅股票</li>
<li>投資者如何識別併成功交易缺口下跌股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 OmniAb 嗎？</h2>
<p>在你考慮 OmniAb 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買...而 OmniAb 並不在名單上。</p>
<p>雖然 OmniAb 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OABI

<p>OmniAb, Inc. 的內部人士 Charles Berkman 以每股 1.96 美元的價格出售了 8,044 股，總計 15,766.24 美元。出售後，Berkman 擁有 377,071 股，持股比例減少了 2.09%。該交易已在 SEC 文件中披露。OmniAb 的股票開盤價為 1.99 美元，市值為 2.8648 億美元。分析師對該公司的共識評級為 “適度買入”，目標價格為 6.67 美元。該公司報告第三季度每股虧損 0.14 美元，略好於預期</p>

<p>OmniAb, Inc. (NASDAQ:OABI - Get Free Report) insider Charles Berkman sold 8,044 shares of OmniAb stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $1.96, for a total value of $15,766.24. Following the sale, the insider directly owned 377,071 shares of the company's stock, valued at approximately $739,059.16. The trade was a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>OmniAb, Inc.（納斯達克代碼：OABI - 獲取免費報告）內部人士 Charles Berkman 於 12 月 8 日星期一出售了 8,044 股 OmniAb 股票。該股票的平均售價為 1.96 美元，總價值為 15,766.24 美元。出售後，該內部人士直接持有公司 377,071 股股票，估值約為 739,059.16 美元。此次交易使其持股比例減少了 2.09%。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，相關信息可通過 SEC 網站訪問。</p>
</div><h2>OmniAb Price Performance</h2>
<div class="lb-trans"><h2>OmniAb 價格表現</h2>
</div><p>Shares of NASDAQ OABI opened at $1.99 on Tuesday. The firm has a market cap of $286.48 million, a price-to-earnings ratio of -3.43 and a beta of 0.13. The stock's fifty day moving average price is $1.65 and its two-hundred day moving average price is $1.71. OmniAb, Inc. has a one year low of $1.22 and a one year high of $4.17.</p>
<div class="lb-trans"><p>納斯達克 OABI 的股票在星期二開盤價為 1.99 美元。該公司的市值為 2.8648 億美元，市盈率為-3.43，貝塔值為 0.13。該股票的 50 日移動平均價格為 1.65 美元，200 日移動平均價格為 1.71 美元。OmniAb, Inc.的年內最低價為 1.22 美元，最高價為 4.17 美元。</p>
</div><p>OmniAb (NASDAQ:OABI - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The company had revenue of $2.24 million during the quarter, compared to the consensus estimate of $5.64 million. On average, equities analysts anticipate that OmniAb, Inc. will post -0.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>OmniAb（納斯達克：OABI - 獲取免費報告）最近一次發佈財報是在 11 月 4 日星期二。公司報告本季度每股收益為（0.14）美元，超出分析師一致預期的（0.15）美元，超出幅度為 0.01 美元。OmniAb 的股本回報率為負的 23.14%，淨利潤率為負的 301.83%。該公司本季度的收入為 224 萬美元，而一致預期為 564 萬美元。平均而言，股票分析師預計 OmniAb, Inc.在當前財政年度的每股收益為-0.61 美元。</p>
</div><h2>Hedge Funds Weigh In On OmniAb</h2>
<div class="lb-trans"><h2>對 OmniAb 的對沖基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its position in shares of OmniAb by 20.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company's stock valued at $78,000 after buying an additional 7,624 shares in the last quarter. Murchinson Ltd. boosted its position in shares of OmniAb by 0.8% during the 1st quarter. Murchinson Ltd. now owns 1,007,810 shares of the company's stock worth $2,419,000 after acquiring an additional 7,810 shares in the last quarter. Rhumbline Advisers increased its stake in OmniAb by 6.0% in the second quarter. Rhumbline Advisers now owns 160,728 shares of the company's stock valued at $280,000 after acquiring an additional 9,163 shares during the last quarter. Osaic Holdings Inc. raised its position in OmniAb by 214.4% during the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock valued at $25,000 after purchasing an additional 9,716 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in OmniAb during the first quarter valued at approximately $25,000. 72.08% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金最近買入和賣出了該公司的股票。製造商人壽保險公司在第二季度將其在 OmniAb 的持股比例提高了 20.5%。製造商人壽保險公司現在持有 44,809 股公司股票，價值 78,000 美元，此前在上個季度又購買了 7,624 股。Murchinson Ltd.在第一季度將其在 OmniAb 的持股比例提高了 0.8%。Murchinson Ltd.現在持有 1,007,810 股公司股票，價值 2,419,000 美元，此前在上個季度又收購了 7,810 股。Rhumbline Advisers 在第二季度將其在 OmniAb 的持股比例提高了 6.0%。Rhumbline Advisers 現在持有 160,728 股公司股票，價值 280,000 美元，此前在上個季度又收購了 9,163 股。Osaic Holdings Inc.在第二季度將其在 OmniAb 的持股比例提高了 214.4%。Osaic Holdings Inc.現在持有 14,247 股公司股票，價值 25,000 美元，此前在上個季度又購買了 9,716 股。最後，AQR Capital Management LLC 在第一季度收購了 OmniAb 的新頭寸，價值約為 25,000 美元。72.08% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of OmniAb in a report on Monday, December 1st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $6.67.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 1 日星期一的報告中重新發布了對 OmniAb 股票的 “賣出（d-）” 評級。三位投資分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，共識目標價為 6.67 美元。</p>
</div><p><strong>View Our Latest Analysis on OmniAb</strong></p>
<div class="lb-trans"><p><strong>查看我們對 OmniAb 的最新分析</strong></p>
</div><h2>About OmniAb</h2>
<div class="lb-trans"><h2>關於 OmniAb</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.</p>
<div class="lb-trans"><p>OmniAb, Inc.是一家生物技術公司，專注於在美國發現和提供治療性抗體發現技術。該公司的技術平台創建並篩選多樣化的抗體庫，併為合作伙伴的藥物開發工作識別最佳抗體。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than OmniAb</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Why These 3 Automotive &amp; Industrial Chip Stocks Just Soared</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Top 5 Highest-Rated Dividend Stocks, According to MarketBeat</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 OmniAb 更好</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>為什麼這三隻汽車和工業芯片股票剛剛飆升</li>
<li>什麼是分紅成就者？簡介</li>
<li>根據 MarketBeat，評級最高的五隻分紅股票</li>
<li>投資者如何識別併成功交易缺口下跌股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=OABI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OmniAb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 OmniAb 嗎？</h2>
</div><p>Before you consider OmniAb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 OmniAb 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買...而 OmniAb 並不在名單上。</p>
</div><p>While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 OmniAb 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

OmniAb (NASDAQ:OABI) 內部人士 Charles Berkman 出售了 8,044 股股票